Diabetes & EndocrinologysemaglutideGLP-1 receptor agonist
Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial
By MedXY|Aug 27, 2026
This phase 2b trial evaluates bofanglutide’s efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.